menu
    • menu
    [{"orgOrder":0,"company":"Amgen Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Apremilast","moa":"PDE4","graph1":"Dermatology","graph2":"Approved","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Amgen Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amgen Inc \/ Not Applicable"},{"orgOrder":0,"company":"Global Coalition for Adaptive Research","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Apremilast","moa":"PDE4","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Global Coalition for Adaptive Research","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Global Coalition for Adaptive Research \/ Not Applicable","highestDevelopmentStatusID":"11","companyTruncated":"Global Coalition for Adaptive Research \/ Not Applicable"},{"orgOrder":0,"company":"Unichem Laboratories Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Apremilast","moa":"PDE4","graph1":"Dermatology","graph2":"Approved","graph3":"Unichem Laboratories Limited","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Unichem Laboratories Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Unichem Laboratories Limited \/ Not Applicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Apremilast","moa":"PDE4","graph1":"Dermatology","graph2":"Approved","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Amgen Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amgen Inc \/ Not Applicable"},{"orgOrder":0,"company":"Shilpa Medicare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Apremilast","moa":"PDE4","graph1":"Immunology","graph2":"Approved","graph3":"Shilpa Medicare","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Shilpa Medicare \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Shilpa Medicare \/ Not Applicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Apremilast","moa":"PDE4","graph1":"Dermatology","graph2":"Approved","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Amgen Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amgen Inc \/ Not Applicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Apremilast","moa":"PDE4","graph1":"Dermatology","graph2":"Approved","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Zydus Lifesciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Zydus Lifesciences \/ Not Applicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Apremilast","moa":"PDE4","graph1":"Dermatology","graph2":"Approved","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Amgen Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amgen Inc \/ Not Applicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Apremilast","moa":"PDE4","graph1":"Dermatology","graph2":"Approved","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Amgen Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amgen Inc \/ Not Applicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Apremilast","moa":"PDE4","graph1":"Dermatology","graph2":"Approved","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Amgen Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amgen Inc \/ Not Applicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Apremilast","moa":"PDE4","graph1":"Dermatology","graph2":"Approved","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Amgen Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amgen Inc \/ Not Applicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Apremilast","moa":"","graph1":"Dermatology","graph2":"Approved","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Amgen Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amgen Inc \/ Not Applicable"},{"orgOrder":0,"company":"Tiefenbacher Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Apremilast","moa":"","graph1":"Dermatology","graph2":"Approved","graph3":"Tiefenbacher Group","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Tiefenbacher Group \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Tiefenbacher Group \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Apremilast

    Menu

    Apremilast

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Tiefenbacher Group

                            Germany
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothWe are the TIEFENBACHER GROUP, Health Pioneers since 1963.

                            Lead Product(s) : Apremilast

                            Therapeutic Area : Dermatology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Tiefenbacher Pharmaceuticals Successfully Launches Generic Version of The Psoriasis Medication Apremilast in C...

                            Details : Otezla-Generic (apremilast) is an inhibitor of phosphodiesterase 4 (PDE4). It is indicated for the treatment of adult patients with moderate to severe plaque psoriasis, active psoriatic arthritis, and oral ulcers.

                            Brand Name : Otezla-Generic

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            December 01, 2022

                            Lead Product(s) : Apremilast

                            Therapeutic Area : Dermatology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            Tiefenbacher Compnay Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Amgen Inc

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Amgen Inc

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Apremilast

                            Therapeutic Area : Dermatology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Amgen Wins Patent Appeal on Otezla® (apremilast)

                            Details : Otezla® (apremilast) is an oral small-molecule inhibitor of phosphodiesterase 4 (PDE4) specific for cyclic adenosine monophosphate (cAMP), indicated for the treatment of plaque psoriasis in adults.

                            Brand Name : Otezla

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            April 19, 2023

                            Lead Product(s) : Apremilast

                            Therapeutic Area : Dermatology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Amgen Inc

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Amgen Inc

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Apremilast

                            Therapeutic Area : Dermatology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Amgen Announces Positive New Data At EADV 2022 For Otezla® (Apremilast)

                            Details : 16-week data demonstrated clinically meaningful and statistically significant improvement in genital psoriasis, with twice many patients achieving primary endpoint of clear (0) or almost clear (1) sPGA-G scale receiving Otezla (apremilast) when compared ...

                            Brand Name : Otezla

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            September 08, 2022

                            Lead Product(s) : Apremilast

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Amgen Inc

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Amgen Inc

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Apremilast

                            Therapeutic Area : Dermatology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Amgen to Present New, Positive Clinical and Real-World Data Across Inflammation Portfolio At EADV 2022

                            Details : Presentations will cover a range of clinical data for Otezla® (apremilast), including positive, 16-week results from the Phase 3 SPROUT study in children ages 6-17 with moderate to severe plaque psoriasis.

                            Brand Name : Otezla

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            August 30, 2022

                            Lead Product(s) : Apremilast

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Amgen Inc

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Amgen Inc

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Apremilast

                            Therapeutic Area : Dermatology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Amgen Announces New Otezla (Apremilast) Data at AAD Congress 2022

                            Details : New data further reinforces clinical benefit of Otezla (apremilast) is an oral small-molecule inhibitor of phosphodiesterase 4 in mild to moderate plaque psoriasis and in patients with palmoplantar pustulosis.

                            Brand Name : Otezla

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            March 25, 2022

                            Lead Product(s) : Apremilast

                            Therapeutic Area : Dermatology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Amgen Inc

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Amgen Inc

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Apremilast

                            Therapeutic Area : Dermatology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            FDA Approves Otezla® (Apremilast) for The Treatment of Adult Patients with Plaque Psoriasis, Regardless of Se...

                            Details : The adverse events observed in the trial were consistent with the known safety profile of Otezla. The most commonly reported (≥5%) treatment-emergent adverse events with Otezla treatment were diarrhea, headache, nausea and nasopharyngitis.

                            Brand Name : Otezla

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            December 20, 2021

                            Lead Product(s) : Apremilast

                            Therapeutic Area : Dermatology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Zydus Lifesciences

                            India arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Zydus Lifesciences

                            India arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Apremilast

                            Therapeutic Area : Dermatology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Zydus Cadila gets US FDA Marketing Approval for Apremilast Tablets

                            Details : Zydus Pharmaceuticals (USA) Inc. has received final approval from the US Food and Drug Administration (FDA) to market apremilast tablets in the strengths of 10 mg, 20 mg, 30 mg tablets are indicated for treatment of adult patients with plaque psoriasis.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            September 24, 2021

                            Lead Product(s) : Apremilast

                            Therapeutic Area : Dermatology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Amgen Inc

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Amgen Inc

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Apremilast

                            Therapeutic Area : Dermatology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            FDA Accepts Amgen's Supplemental New Drug Application For Otezla® (Apremilast) For Adults With Mild-To-Modera...

                            Details : Otezla® (apremilast) has potential to be first and only approved oral therapy for the mild-to-moderate patient population. Acceptance based on data from Phase 3 ADVANCE Study, demonstrating clinically meaningful improvements through week 32.

                            Brand Name : Otezla

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            May 05, 2021

                            Lead Product(s) : Apremilast

                            Therapeutic Area : Dermatology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Shilpa Medicare

                            India arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Shilpa Medicare

                            India arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Apremilast

                            Therapeutic Area : Immunology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Shilpa Medicare Gets Tentative American Health Regulator Nod for Apremilast Tablets

                            Details : The company has received tentative approval from US Food and Drug Administration for its abbreviated new drug application (ANDA) Apremilast tablets in the strengths of 10 mg, 20 mg, and 30 mg, Shilpa Medicare said in a regulatory filing.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            March 05, 2021

                            Lead Product(s) : Apremilast

                            Therapeutic Area : Immunology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Amgen Inc

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Amgen Inc

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Apremilast

                            Therapeutic Area : Dermatology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Amgen Submits Supplemental New Drug Application for Otezla® (apremilast) for Adults with Mild-To-Moderate Pla...

                            Details : The sNDA is based on data from the Phase 3 ADVANCE trial that demonstrated oral Otezla 30 mg twice daily achieved a statistically significant improvement in the primary endpoint of the static Physician's Global Assessment (sPGA) response at week 16 compa...

                            Brand Name : Otezla

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            February 22, 2021

                            Lead Product(s) : Apremilast

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth